Cystic Fibrosis Trial, Recruiting NCT07245407 Sponsor: AstraZeneca Condition: Cystic Fibrosis
Back to Cystic Fibrosis

Cystic Fibrosis Trial, Recruiting

NCT07245407
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Healthy volunteer group:

  • You are 30 years of age or older

Bronchiectasis patient group:

  • You are 18 years of age or older
  • You have been diagnosed by a doctor with bronchiectasis, supported by symptoms (such as long-term cough and daily mucus production) and a chest CT scan confirming the condition
  • You are able to do breathing/lung function tests following standard guidelines
  • You are able to read, write, and are comfortable using electronic devices (such as a breath test device and a digital spirometer)
  • You are willing and able to follow all study requirements
  • Your condition is currently stable, or if you recently had a flare-up (worsening of symptoms), at least 4 weeks have passed since it ended before joining the main study visits
  • You are able to give your signed agreement to take part in the study

Who may not be able to join:

Healthy volunteer group:

  • You have been diagnosed with any breathing or lung condition, such as asthma, COPD, bronchiectasis, or pulmonary fibrosis
  • You have an inflammatory condition such as rheumatoid arthritis, inflammatory bowel disease, or a similar connective tissue disease
  • You currently have an active cancer (except for a common type of minor skin cancer called non-melanoma skin cancer)
  • You have taken antibiotics for a chest or breathing infection in the past 4 weeks, or you currently have a sinus infection
  • You currently smoke or have smoked in the past 3 months
  • You are taking blood-thinning medication (anti-coagulants)
  • You have any medical reason that would make the study procedures, including a bronchoscopy (a camera procedure to look inside the airways), unsafe for you

Bronchiectasis patient group:

  • Your bronchiectasis is caused by scarring from another lung condition such as pulmonary fibrosis or cystic fibrosis
  • Your main lung condition is something other than bronchiectasis, such as COPD or asthma (though having these as a secondary condition may still be acceptable — confirm with trial site)
  • You have another serious health condition (for example, affecting your heart, liver, kidneys, nerves, mental health, or other body systems) that is not stable and could affect your safety, influence the study results, or prevent you from completing the study (confirm with trial site)
  • You have had problems with alcohol or drug misuse in the past year that the doctor feels would make participation unsafe
  • You currently have an active cancer (except for a common type of minor skin cancer called non-melanoma skin cancer)
  • You are pregnant, breastfeeding, up to 6 weeks after giving birth, or within 6 weeks of stopping breastfeeding
  • You have a cold, chest infection, or any other upper or lower respiratory infection or symptoms within 2 weeks of your first study visit
  • Your mental state at the time of signing the consent form means you are unable to fully understand and agree to taking part
  • You are considered by the medical team to be too unwell to participate, including having a terminal illness or organ failure
  • You are involved in planning or running this study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jinfu Xu, Doctor, Shanghai Tongji Hospital, Tongji University School of Medicine

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
27 October 2025
Est. completion
29 July 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

FEV1/FVC%; FEF25-75 L/s; FENO ppb; HRCT; cell percentage (%); Gene expression read counts by RNAseq; Molecular deliverables; on-set age(years-old); Sex(M/F); body mass index(kg/m^2); comorbidities; medical history; smoking status(never/current/former); smoking pack years(pack/year); Sputum microbiology (CFU); Historical Exacerbation; BSI score; QoL-B-RSS; BHQ; BEST; Treatment pattern; Exacerbation assessment; Cell counts (10^9/L); Exacerbation assessment about hospitalization

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov